Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + sintilimab + irinotecan + paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + sintilimab + irinotecan + paclitaxel is a combination therapy regimen being evaluated for the treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma. The regimen consists of apatinib, a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit tumor angiogenesis; sintilimab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor to restore anti-tumor immune activity; and cytotoxic chemotherapy, either irinotecan (a topoisomerase I inhibitor) or paclitaxel (a microtubule stabilizer). This multi-modal approach, investigated in a Phase II study at Tianjin Medical University Cancer Institute and Hospital, aims to leverage the synergistic effects of anti-angiogenic therapy, immune checkpoint inhibition, and traditional chemotherapy in patients who have failed prior treatments.
- Other names
- RivoceranibApatinib mesylateIrinotecanPaclitaxel
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + sintilimab + irinotecan + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + sintilimab + irinotecan + paclitaxel.